Optimizing resources: financial evaluation of flow diverters versus stent assisted coiling in large and giant cerebral aneurysm management in Brazil public health system.

BACKGROUND: Cerebral aneurysms, especially large and giant aneurysms, pose challenges in neurointerventional surgery. Treatment choices involve clinical presentation, aneurysm details, and global resource variations. Neurointerventional methods, while innovative, may be cost restrictive in certain regions. In public healthcare, cost is crucial, notably in countries like Brazil. This study examines the device specific cost estimation of flow diverters (FD) and traditional stent assisted coiling (SAC) for large and giant cerebral aneurysms, providing insights into optimizing neurosurgical interventions within the Brazilian public health system's unique challenges. METHODS: A comprehensive retrospective analysis was conducted at our medical center of cases of large and giant aneurysms treated between 2013 and 2023. Determination of the estimated number of coils for aneurysms previously treated with FDs at our center was made, with the cost of each case, and the difference between both treatments was calculated. RESULTS: We investigated the profiles of 77 patients: 40 had large aneurysms (51.9%) and 37 had giant aneurysms (48.1%). Large aneurysms had a mean cost difference of US$274 (standard deviation (SD) $2071), underscoring the device specific cost estimation of FDs over SAC in their treatment. For giant aneurysms, the mean cost difference increased to $6396 (SD $2694), indicating FDs as the more economically sound choice. CONCLUSION: Our study indicated that, for the treatment of giant aneurysms and some large aneurysms, the FD intervention was more economical than SAC.

Therapeutic anticoagulation for venous thromboembolism after recent brain surgery: Evaluating the risk of intracranial hemorrhage.

OBJECTIVE: Venous thromboembolism (VTE) is particularly prevalent in neurosurgical patients. A major dilemma arises when a patient needs to be treated with therapeutic anticoagulation during the early days after brain surgery due to the concern of intracranial hemorrhage (ICH). There is still a lack of studies regarding the optimal time to start therapeutic anticoagulation and risk assessment of ICH in this setting. This study aims to assess the risk of ICH for patients with venous thromboembolism treated with therapeutic anticoagulation started within the first 30 days after intracranial neurosurgical procedure. PATIENTS AND METHODS: This study was an analytical observational research based on a retrospective record review of VTE patients submitted to therapeutic anticoagulation started within the first 30 days after intracranial neurosurgical procedure at Paulo Niemeyer State Brain Institute, from September 2013 to February 2020. Patients' clinical and surgical data, anticoagulation drug therapy, time interval between surgery and start of therapeutic anticoagulation, bleeding complications and hemorrhage-related deaths were some of variables evaluated. A p value < 0.05 was considered statistically significant. RESULTS: A series of 53 consecutive patients and 54 intracranial neurosurgical procedures met the criteria. Twenty-nine (53.7 %) patients were treated with warfarin, 21 (38.9 %) with new oral anticoagulant (NOAC) and 4 (7.4 %) only with enoxaparin. VTE diagnosis between the postoperative days 0 and 4 was statistically associated with a delay in starting therapeutic anticoagulation of more than two days (p < 0.001). The frequency of bleeding complication was statistically significant higher in patients treated with warfarin (p = 0.03). Although with no statistical significance, there were a higher rate of ICH in patients receiving warfarin (13.8 % vs. 0% in NOAC group, p = 0.13). There was no statistical difference about ICH incidence between the postoperative intervals from 2nd to 7th, 8th to 14th, 15th to 21 st and 22th to 29th days (p = 0.35). Hemorrhage-related mortality rate was 3.7 %. CONCLUSION: ICH was not statistically associated with the timing of therapeutic anticoagulation after brain surgery between the 2nd and 29th postoperative days, which may encourage the strategy of early treatment considering the life-threatening potential of VTE. However, the risk of ICH should not be ignored in the setting of warfarin use, which had a remarkable incidence of 13.8 %. Warfarin must be used cautiously, especially in high-grade gliomas.

Reabilitação nasal por prótese maxilofacial / Nose prosthetic rehabilitation by maxillofacial prosthesis

Este artigo descreve uma técnica de confecção de prótese nasal em paciente do sexo feminino, 70 anos, com perda total das estruturas nasais por carcinoma espinocelular. Esta técnica adotou como procedimento a reprodução do nariz em modelina, onde foram esculpidas as configurações anatômicas de interesse. Após moldagem das estruturas faciais remanescentes com hidrocolóide irreversível, foi feito modelo de gesso tipo IV, sobre o qual foi realizado todo o trabalho de escultura da peça protética. Após a prova estética e seleção aproximada da cor base, a peça foi incluída em gesso tipo III e processada com resina acrílica termopolimerizável através de ciclo rápido. As caracterizações de cor e nuanças de sombra foram feitas no interior do molde, com inclusão de pigmentos acrílicos durante inclusão da resina. O resultado estético foi bastante satisfatório e a prótese encontra-se atualmente sob controle